News

Investment will grow manufacturing capabilities at Winchester site

East Syracuse site will serve as a hub for company’s US biologics CDMO business

Should be administered at least five months after the second dose of the two-dose primary series

Deal establishes company’s presence in Mexico

It is the first solution that allows pharma and biotech to design, set up, plan, orchestrate, and scale APT supply chains with one single system, the company reports

Will be investing up to $100 million to expand presence in Taiwan

Company anticipating to double global network size by end of the year

Among functions, 80,000 square-foot space will house a 'Center of Excellence'

Location will feature aseptic fill-finish technology

Pfizer to commercialize NURTEC® ODT, an innovative compound for the prevention and acute treatment of migraine

Per supply chain agreement, CDMO will provide analytical product support

Among efforts, part of center’s focus revolves providing tools for product commercialization

New partnership focused on improving quality of care, patient outcomes and safety in health systems

Facility will feature biologic manufacturing, along with late-stage research and clinical development of cancer medicines

Decrease influenced by various worldwide economic developments, IATA says

New slices of the data will focus on key accounts, scientific awareness and medical insights

Expected to be ready by mid-2024

Cambridge, MA facility to be home to Alexion corporate HQ

The latest people news happenings over the past month

Facility adds to company’s global network

Series of documents promotes best practices for managing and measuring data quality

Deal for New Jersey cell therapy site totals $44.5 million

New location in London, UK

Commercial-scale center will cost $650 million, featuring 144,000 liters of biomanufacturing capacity

Deal adds biopharma services to its capabilities

Will address biologics drug substance and drug product manufacturing services

Nominal revenue for US drug sales was up to $776 billion, reports IQVIA, but net revenue (discounting rebates) was $407 billion. Some $29 billion was spent on COVID-19 vaccines and therapeutics

Factory will reportedly provide capability of manufacturing 3-4 vaccines simultaneously